A pre-clinical rationale for targeting the c-MET pathway in patients with relapsed and resistant MM was previously suggested in a manuscript by Moschetta et al.[35] evaluating the activity of the c-MET inhibitor SU11274 in MM cell lines, either sensitive or resistant to anti-myeloma drugs. The gene discussed is MET; the disease is plasma cell myeloma.